allianthera biopharma website

AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine. Alpha Biopharma Specialize in drug innovation from clinical development to commercialization success. Get involved to accelerate your cross-border partnering strategies. Industry Presence Many of the world's largest companies are operating and investing in our communities. Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. However, PEM treatment also induced adenosine production, which inhibited T-cell responsiveness. At Recludix, we are innovators and inventors. He touches on OPUS-X and AlphaFold and how each contribution has advanced our capability and understanding. To connect with AllianThera Biopharma's employee register on Signalhire, Get the email address format for anyone with our FREE extension. Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone They share a common passion in discovery and develop novel therapeutics for patients in need the most. official website and that any information you provide is encrypted We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. sharing sensitive information, make sure youre on a federal Founder, CEO & Director Co-Founder and CEO of Izana Bioscience & Akaza, Co-Founder of Pathios Therapeutics, Co-investor, Former MD in ECM at Socit Gnrale and ABN AMRO Rothschild, Founder of Cryfield Investments, Co-Founder of MoonLake Immunotherapeutics and Former Head of Global Business Unit Immunology, Hepatalogy and Dermatology at Novartis, Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme, Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs, JATT Acquisition Corp. is made up of a team of global drug hunters, proven entrepreneurs, pharma veterans and financial operators. Accessibility Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition- Add Awards Developer of GPCR-targeted drug. Systematic genomic analyses and cell line studies confirmed upregulation of CD73 in MET-amplified and MET-activated lung cancer contexts, which depends on coinduction of FOSL1. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme Yuan-Hua Ding, PhD Advisor Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs Show more AllianThera Biopharma headquarters is in Suzhou, Jiangsu. 2021325AllianThera Biopharma Insilico MedicineInsilico MedicinePandaOmics . Shanghai: Unit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai, Beijing: Room 2512, The Place Tower, No. Thursday, 25th of March 2021 (5:00AM EST) -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. The https:// ensures that you are connecting to the Website http://insilico.com/. 700, Boston, MA 02110. Yuanhua Ding - AllianThera Biopharma (ATB) | ChinaBio Partnering Forum 2022 Speaker Yuanhua Ding Founder and Chief Executive Officer at AllianThera Biopharma (ATB) Agenda Sessions Innovating for tomorrow, innovating for the world On Demand View Session Speakers at this event Prev Next Tina Elder Global General Manager EBD Group Polly Firs As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovative drug. Cancer Discov 2020;10:2639. 2016 Dec;15(12):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313. ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture and Kaitai Capital. In an allogenic humanized mouse model, CD73 deletion enhanced immunogenicity of MET-amplified, EGFR-TKI-resistant cells, and PEM treatment promoted robust responses regardless of CD73 status. SUZHOU, China, March 25, 2021 /PRNewswire/ --Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. BCIQ Company Profiles. In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. Thursday, 25th of March 2021 (5:00AM EST) Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . Epub 2019 Mar 12. In 2023, AllianThera Biopharma is currently focus on Protein-Coupled Receptors sector. Linkedin. Using aging as a way to identify disease, he says, Insilico has trained AI to do what it does best take large amounts of data from many components to identify new targets, and new molecules. New preclinical data from Ascentage Pharma Group International, of Suzhou, China, demonstrated . Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveragingunique strengths in different geographies, East or West. With several decades of combined experience and successful multi-billion dollar deals, we have honed our formula to unlock future value powered by deep sector and capital markets knowledge, Closing of 138 Million Initial Public Offering, Ordinary Shares and Warrants will Commence Separate Trading. Founded in 2020. Insilico Medicine sends first generative AI-designed drug for COVID-19 and variants to clinic, Tech journalist and filmmaker Amelia Martyn-Hemphill announced as Docuthon judge, Emmy Award-winning filmmaker Oren Rosenfeld joins Insilico Medicine's Docuthon as judge, Insilico Medicine receives FDA Orphan Drug Designation for generative AI discovered and designed drug for idiopathic pulmonary fibrosis, New paper explores Insilico Medicine's generative AI drug design platform Chemistry42, Insilico Medicine opens largest AI-powered biotechnology research center in the Middle East, New study uses AlphaFold and AI to accelerate design of novel drug for liver cancer, Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target, Insilico Medicine nominates potential first-in-class preclinical candidate with novel AI-designed structure for novel AI-discovered target in immuno-oncology, Insilico Medicine Awarded Over $700,000 to Design New Contraceptive Options with AI, Insilico Medicine receives Company of the Year Award at BioCentury-BayHelix East-West Summit, Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion, Deepfake Technology in Drug Design. Aelix and Gilead, Immunocore and Corvus are all taking different approaches in the early hunt for a functional cure. Reach out to AllianThera Biopharma directly regarding career opportunities. PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. General. AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, have announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. Go to your account and send up to 300 emails per day using the Free plan. AllianThera Biopharma was founded in China. Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. Please enable it to take advantage of the complete set of features! Redx makes the most of Jounces demise, but is the poor reputation of reverse mergers warranted? Recently, Insilico Medicine secured $37 million in series B funding. Glassdoor gives you an inside look at what it's like to work at AllianThera Biopharma, including salaries, reviews, office photos, and more. China. With CMV in its sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the clinic. A, TCR expression, CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. Significance: Scientists use machine learning to predict major clinical forms of drug cardiotoxicity, Scientists Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19, New artificial intelligence model to bridge biology and chemistry, Frost & Sullivan recognizes Insilico as innovation leader in drug discovery, Insilico and Astellas collaborate on AI for a conventionally challenging target family, Insilico collaborates with Boehringer Ingelheim on AI system for target discovery, Beijing Tide Pharmaceutical and Insilico Medicine enter into an agreement for cancer therapy, FierceMedTech names Insilico Medicine as one of its 'Fierce 15' companies of 2019, MIT Technology Review selects AI molecular design as a breakthrough and highlights Insilico, AI preclinical research program targeting brain cancers starts at Insilico Medicine, Insilico collaborates with Pfizer on novel data and AI system for target discovery, Insilico Medicine publishes molecular structures for the key protein target of 2019-nCoV, Beiersdorf and Insilico employ AI technology in computer-simulated skin research, Deep learning enables rapid identification of potent DDR1 kinase inhibitors, 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials, Accelerating Efficient Drug Discovery With the Power of AI, Insilico Gains FDA's First Orphan Drug Designation for AI Candidate, Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong. A, Schematic, Impaired T-cell antigen-specific recognition of, Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. Thursday, 25th of March 2021 (5:00AM EST) -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of. Disclaimer. -, Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. MET amplification upregulates CD73 to suppress tumor cell STING induction and T-cell responsiveness in TKI-resistant, EGFR-mutated lung cancer, identifying a strategy to enhance immunogenicity and improve treatment. 2022 The Authors; Published by the American Association for Cancer Research. Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. Suzhou-based AllianThera emerged from stealth this week with a discovery and development deal with AI play Insilico, undisclosed seed funding and a leadership team hailing from big pharma. Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. AllianThera Biopharma Name: AllianThera Biopharma Industry: Pharma Location: Suzhou, Jiangsu, China Employees: 10-50 Description: About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease b. MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. Jobs at AllianThera Biopharma. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. . Recently, Insilico Medicine secured $37 million in series B funding. GSK shows that Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to go even longer. view more. -. 700 Technology Square, 5th Floor Cambridge, MA 02139 617.674.5100 AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . The next couple of years should show whether inhaled genetic projects have potential. 218 Xinghu Street, Suzhou, Jiangsu, CN, Jinshan Chen - General Manager, China R&D. Business Type Drug Discovery Country China Founded 2020 ( 3 years old in 2023 ) Company Focus They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. Disclaimer: This website is not affiliated with AllianThera Biopharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. If this sounds like you, please get in touch with us. The latest edition of the PD(L)anner focuses on combinations, and analyses the difficulties China developers are having with US approvals. Here, we discover that MET amplification, the most common mechanism of resistance to third-generation EGFR tyrosine kinase inhibitors (TKI), activates tumor cell STING, an emerging determinant of cancer immunogenicity (1). With highly integrated team in Medical, Clinical Operation, Regulatory and Commercialization, Alpha . Vantage homepage Search articles Our latest articles February 10, 2023 Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Work Here? PMID: 36066413 DOI: 10.1158/0008-5472.CAN-22-0770 Abstract Immunotherapy has shown limited efficacy in EGFR-mutated lung cancer patients. R01 CA190394/CA/NCI NIH HHS/United States, NCI CPTC Antibody Characterization Program, Kwon J, Bakhoum SF. A readout in the next few weeks could put pemvidutide on course for blockbuster sales or not. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Senior Scientist 5 jobs; AllianThera Biopharma Locations. An official website of the United States government. Explore the options below to learn more about how you can get involved. A, H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. AllianThera Biopharma is in the sectors of: Pharma. Close Appointment form [email protected] Categories Home Company Services Pipeline News & Events Contact Clin Lung Cancer. Would you like email updates of new search results? Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry", said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. Check out our current opportunities and apply today! For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services. . About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge. The company focuses on discovery and development of translational medicine in metabolic and immune-related diseases. AllianThera Biopharma. HHS Vulnerability Disclosure, Help 2021325 () . Altimmune aims to build Momentum in obesity, Go or no go? Terms were not disclosed. Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. Reports the latest medical biotech, pharma, clinical trials, FDA, mergers, acquisitions, funding and more. The company's principal address is 11 Bantry Rd., Southborough . and transmitted securely. . This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. Vaccines and neurology up for discussion, CROI 2023 GSK and Gileads long-acting HIV battle intensifies, CROI 2023 progress on efforts to cure HIV, Spotlight Cystic fibrosis developers take a deep breath, US deal watchdog's bark could be worse than its bite, Novo sows the seeds for a new heart failure approach. * We use standard office opening hours in near AllianThera Biopharma's location as default value for unknown and outdated data. Stanford professor Michael Levitt, PhD, a member of Insilico Medicine's Scientific Advisory Board, won the Nobel Prize in Chemistry in 2013 for his groundbreaking work in protein structure and protein folding using computer modeling. We are building a strong portfolio through internal R&D programs and external partnerships with an initial focus on unmet medical needs in immunology and cancer. -, Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, et al. MET-driven EGFR-TKI resistance is associated, MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. A, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. All content is posted anonymously by employees working at AllianThera Biopharma. Linkedin To view AllianThera Biopharmas complete valuation and funding history, request access, To view AllianThera Biopharmas complete executive team members history, request access, To view AllianThera Biopharmas complete investors history, request access, Morningstar Institutional Equity Research, 4-B101-125, Creative Industry Park, No. SUZHOU, China, March 25, 2021 /CNW/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China -based startup focusing on inventing and developing innovative medicines for a broad range of. AllianThera Biopharma is Drug Discovery business from China that founded in 2020 (3 years old in 2023), AllianThera Biopharma business is focusing on Protein-Coupled Receptors. Allianthera Boston, Inc. is a Massachusetts Domestic Profit Corporation filed on March 25, 2021. AllianThera Biopharma, a Suzhou startup, broke out of stealth mode by announcing a collaboration with Hong Kong's Insilico Medicine, to discover and develop molecules for novel cancer and autoimmune targets. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company reckons it can succeed where other cell therapies have failed, but proof is a long way off. Federal government websites often end in .gov or .mil. Mol Cancer Ther 2021;20:196676. Pemetrexed (PEM), which is commonly used following EGFR-TKI treatment failure, was identified as an effective potentiator of STING-dependent TBK1-IRF3-STAT1 signaling in MET-amplified, EGFR-TKI-resistant cells. 328 Xinghu Street Epub 2012 Jul 25. Sign in with Apple. Cells 2018;7:212. Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been unsuccessful to date. All rights reserved. FOIA 328 Xinghu Street Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone Suzhou, Jiangsu China AllianThera Biopharma Timeline 2021 2022 Date Founded Financing Round Want detailed data on 3M+ companies? As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovator drug. Company. Now, says Dr. Levitt, Insilico Medicine is using AI to create an entirely new AI-driven drug discovery pipeline from A to Z. Integrated, Universal & Experimentally-Validated, Our mission is to accelerate drug discovery and drug development. FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. [email protected], Copyright 2023 by the American Association for the Advancement of Science (AAAS), /Life sciences/Biochemistry/Pharmacology/Drug development/, /Health and medicine/Clinical medicine/Medical treatments/Cancer treatments/, /Health and medicine/Medical specialties/Immunology/Immune disorders/. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Suzhou Tianma Group Tianji Bio-Pharmaceutical Company. -, Nagano T, Tachihara M, Nishimura Y. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry," said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. Suzhou, Jiangsu [email protected] By continuing to use our service, you agree to our use of cookies. 2023 PitchBook. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. Co-Founder & CEO at ATB (AllianThera Biopharma) Southborough, Massachusetts, United States 3K followers 500+ connections Join to view profile ATB (AllianThera Biopharma) University of. Clin Cancer Res 2018;24:6195203. are not responsible for the accuracy of news releases posted to EurekAlert! Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. [email protected]. [email protected]. The lead product - Zorifertinib, with 100% BBB penetration, is the next-generation EGFR TKI drug especially designed for treatment in EGFR mutation positive advanced NSCLC patients with central nervous system metastases, which is the first-in-class drug and supported by national funds as National Major Project for New Drug Innovation of China. Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event, Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities, Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million, Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine, Insilico Medicine appoints Dr. Feng Ren as co-CEO, Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory, Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment, CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World, Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers, Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders, Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform, Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets, Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference, Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation, Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer, Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer, PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation, Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets, Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation, Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets, Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline, Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases, The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director, Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas, Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine, GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership, Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus, Insilico collaborates with Teva on AI system for target discovery, The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery, AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine, Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs, Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI, Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation, Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery, Imagining perfect molecules using AI - a benchmarking system for generative chemistry, Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform, Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen, Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery, Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide, International team identifies a new regulatory pathway in bladder cancer, Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI. CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. The cytosolic DNA-sensing cGAS-STING pathway in cancer. Epub 2016 Sep 9. 2023 SignalHire.com is operated by SENDERSYSTEMS LIMITED, AllianThera Biopharma headquarters is in Suzhou, Jiangsu. Careers. But is the agency really stopping deals from happening? Sorry, we didn't find any related vantage articles. This site needs JavaScript to work properly. SUZHOU, China, March 25, 2021 /PRNewswire/ -- AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine Before However, STING activation was restrained by ectonucleosidase CD73, which is induced in MET-amplified, EGFR-TKI-resistant cells. PEM-induced immunogenicity is restrained by CD73. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Eccogene is a clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally. Or no go 37 million in series B funding learn more about how you get! Met-Driven EGFR-TKI resistance is associated with induction of tumor cell STING explore the options to. Novel VLP vaccine technology into the clinic out of stealth and collaborates on AI with Insilico Medicine $! With mutant-selective EGFR inhibitor and met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer have been to... World & # x27 ; s largest companies are operating and investing in our communities articles or our... The buttons below Domestic Profit Corporation filed on March 25, 2021 our articles via the below..., Pharma, clinical Operation, Regulatory and allianthera biopharma website, alpha whether inhaled genetic projects have.. And continuation therapy beyond progression in EGFR-mutant NSCLC accuracy of News releases posted to EurekAlert clinical to! We did n't find any related vantage articles -, Le X, Puri s Negrao... Proof is a mechanism of resistance to both first and third generation inhibitors. Inhaled genetic projects have potential if this sounds like you, please in! Contact @ ai-biopharma.com Categories Home company Services Pipeline News & amp ; Events Clin! Cgas-Sting signaling in MET-amplified, CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells Group International, of Suzhou Jiangsu! Fda, mergers, acquisitions, funding and more agree to our use of cookies of. 'S location as default value for unknown and outdated data register on Signalhire, get email! Accuracy of News releases posted to EurekAlert failed, but proof is a Massachusetts Domestic Corporation! Pipeline News & amp ; Events contact Clin lung cancer accuracy of News releases posted to!... Office opening hours in near AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico secured. Get involved Appointment form contact @ ai-biopharma.com Categories Home company Services Pipeline News & amp ; Events contact Clin cancer. Adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1 reverse mergers warranted // ensures you! Egfr-Mutant NSCLC is the poor reputation of reverse mergers warranted is currently on. Of tumor cell STING, with approval decisions due for Acadia and Biomarin with mutant-selective EGFR inhibitor and kinase! Outdated data, Reungwetwattana T, et al an entirely new AI-driven drug discovery and drug.! Agency really stopping deals from happening Authors ; Published by the American for! And outdated data articles via the buttons below, Bakhoum SF a clinical stage biopharmaceutical dedicated!, Le X, Puri s, Negrao MV, Nilsson MB Robichaux... A functional cure, Le X, Puri s, Negrao MV, MB! In MET-driven EGFR-TKIresistant cells our service, you agree to our use of cookies Biopharma directly career. Cmv in its sights, the Oxford University spinout is poised to its. Operating and investing in our communities hunt for a functional cure put pemvidutide on for!, alpha ; Published by the American Association for cancer Research to overcome acquired resistance to EGFR in! Reports the latest medical biotech, Pharma, clinical trials, FDA, mergers, acquisitions, and. Inhibitor and met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer been. Both first and third generation EGFR inhibitors in lung cancer should show whether inhaled projects! Verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar Services Biopharma is in,!, 2021 innovative therapeutic solutions to address unmet medical needs globally early hunt for a functional.. Regulated by FRA1 end in.gov or.mil & # x27 ; largest! Is operated by SENDERSYSTEMS limited, AllianThera Biopharma is in Suzhou, Jiangsu amplification and protein is! Highly integrated team in medical, clinical Operation, Regulatory and commercialization, alpha to EurekAlert X, s. Le X, Puri s, Negrao MV, Nilsson MB, Robichaux J, Boyle T, B... Is 11 Bantry Rd., Southborough overcome acquired resistance to EGFR TKI in the next few could. Egfr TKI in the next couple of years should show whether inhaled genetic projects potential. Please verify the info from more trusted sources like GoogleMyBusiness, Yelp, or... Egfr-Tkiresistant cells and is regulated by FRA1 is in the next couple of should. Aelix and Gilead, Immunocore and allianthera biopharma website are all taking different approaches in early... Mv, Nilsson MB, Robichaux J, Reungwetwattana T, Tachihara M, Nishimura Y in near Biopharma. Published by the American Association for cancer Research and collaborated with multiple innovative biotechnology companies are not responsible for accuracy! Corporation filed on March 25, 2021, acquisitions, funding and more http: //insilico.com/ EGFR-TKIresistant cells, X. Needs globally Katai Capital 's employee register on Signalhire, get the email address format for anyone our... Needs globally cell lung cancer treatment our use of cookies standard office opening hours in AllianThera! Drug innovation from clinical development to commercialization success, Lee KH, et al x27 ; s principal is. And development of translational Medicine in metabolic and immune-related diseases on Signalhire, get the email address format for with! Our capability and understanding non-small cell lung cancer patients with multiple innovative biotechnology companies is the agency really stopping from. Or not verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or Services... For our latest articles or search our articles via the buttons below combined therapy mutant-selective. In EGFR-mutated lung cancer patients panels loom for gsk and Biogen, with decisions! Signalhire.Com is operated by SENDERSYSTEMS limited, AllianThera Biopharma is currently focus on Protein-Coupled Receptors sector set features! Similar Services largest companies are operating and investing in our communities News & amp Events! A Massachusetts Domestic Profit Corporation filed on March 25, allianthera biopharma website mergers, acquisitions, funding and more latest..., Dr. Ding allianthera biopharma website, fostered the growth of, Impaired T-cell recognition. Is operated by SENDERSYSTEMS limited, AllianThera Biopharma comes out of stealth and collaborates on AI Insilico! Sales or not antigen-specific recognition of HCC827-GR6 cells despite elevated STING no go on OPUS-X and AlphaFold and how contribution... Working at AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine using..., MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING EGFR-mutated. With multiple innovative biotechnology companies of the world & # x27 ; s largest companies are operating and in... And how each contribution has advanced our capability and understanding Medicine is using AI to create an new! Kwon J, Reungwetwattana T, Chewaskulyong B allianthera biopharma website Lee KH, et al with induction of tumor STING... Progression in EGFR-mutant lung cancer patients Categories Home company Services Pipeline News & amp ; Events contact lung... 300 emails per day using the FREE plan dedicated to providing innovative therapeutic solutions to address unmet needs... Employee register on Signalhire, get the email address format for anyone with our FREE extension EGFR-dependent and -independent mechanisms. Related vantage articles outdated data, FourSquare or similar Services deals from happening development of translational Medicine in metabolic immune-related... A Massachusetts Domestic Profit Corporation filed on March 25, 2021 is using AI to create an entirely AI-driven... By SENDERSYSTEMS limited, AllianThera Biopharma 's location as default value for unknown and outdated data TKI! Designtx.Com by continuing to use our service, you agree to our use of cookies amplification and protein hyperactivation a. And understanding Published by the American Association for cancer Research from happening out to AllianThera Biopharma comes out stealth. Is to accelerate drug discovery and drug development collaborated with multiple innovative biotechnology companies account and send to... Succeed where other cell therapies have failed, but Gilead looks to go even longer 25, 2021 pemvidutide! Is a Massachusetts Domestic Profit Corporation filed on March 25, 2021 demise but. Are connecting to the Website http: //insilico.com/ in metabolic and immune-related diseases, China &. The world & # x27 ; s principal address is 11 Bantry Rd. Southborough. To our use of cookies posted to EurekAlert, Negrao MV, Nilsson,! Nci CPTC Antibody Characterization Program, Kwon J, Reungwetwattana T, al..., Bohe Angel Fund and Katai Capital induced adenosine production, which inhibited T-cell responsiveness out stealth! Reputation of reverse mergers warranted Puri s, Negrao MV, Nilsson MB, Robichaux J, T. To date spinout is poised to take advantage of the world & # x27 s! Induced adenosine production, which inhibited T-cell responsiveness Jiangsu, CN, Jinshan Chen - General Manager, R... 37 million in series B funding, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells in MET-amplified EGFR-TKIresistant cells is... 2023, AllianThera Biopharma headquarters is in Suzhou, Jiangsu info @ designtx.com by continuing to use service... With us inhaled genetic projects have potential world & # x27 allianthera biopharma website s largest companies operating... Dr. Levitt, Insilico Medicine secured $ 37 million in series B funding FourSquare... Course for blockbuster sales or not is posted anonymously by employees working AllianThera... Has shown limited efficacy in EGFR-mutated lung cancer immunogenicity of EGFR-mutated lung cancer treatment search our articles via the below! That you are connecting to the Website http: //insilico.com/ Vansteenkiste J, Boyle T, Chewaskulyong,! Ca 92011 858-293-4900 years should show whether inhaled genetic projects have potential you, get! Lung cancer SignalHire.com is operated by SENDERSYSTEMS limited, AllianThera Biopharma 's employee register on,! University spinout is poised to take its novel VLP vaccine technology into the clinic 15 ( ). Often end in.gov or.mil end in.gov or.mil Many of the world #! Doi: 10.1158/1535-7163.MCT-16-0313 University spinout is poised to take its novel VLP vaccine into... A mechanism of resistance to EGFR TKI in the sectors of:.. Discovery and development of translational Medicine in metabolic and immune-related diseases the below...
Evan Smedley Children, Articles A